You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
Street Ad dress: Brunnerstrasse 59, A-1235<br />
Wien<br />
Tel: +43 1 86 65 70<br />
Fax: +43 1 86 65 7-575<br />
Home Page: www.novartispharma.at<br />
De scrip tion: De vel oper, im porter, dis trib u tor,<br />
pro moter, sales/detailer. Prod uct ranges in clude:<br />
phar ma ceu ti cal prod ucts (branded, pre scrip tion),<br />
hos pi tal pharmaceuticals, oph thal mic prod ucts.<br />
Es tab lished 1997. 2225 phar ma ceu ti cal em ploy -<br />
ees in 2005. Di vi sions include: Novartis Nutrition.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 100 (2005)<br />
Con tacts (Pharm): Chair man: Chris tian<br />
Seiwald; Com mer cial Op er a tions:<br />
G.Schroeckenfuchs, H. Irschik-Hadjieff, C. Handl,<br />
I. Cip, S. Heise-Grubner; Mar ket Re search: Her -<br />
bert Vorhauer; Re search & De vel op ment:<br />
Wolfgang Bonitz; Gen eral Con tact: Gabi Kollmann<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 240-250 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 35-40%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 45-50%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
80-85%<br />
Prin ci pal Prod ucts:<br />
GLIVEC (antineoplastic other)<br />
CO-DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
ZOMETA (bone cal cium reg u la tor)<br />
VOLTAREN (antirheumatic non-steroidal;<br />
antirheumatic top i cal)<br />
STALEVO (antiparkinson drug)<br />
Ther a peu tic Range:<br />
antineoplastics 15%<br />
renin-an gio ten sin sys tem agents 10%<br />
vac cines 7%<br />
immunosuppressive agents 7%<br />
musculoskeletal drugs other 7%<br />
Lead ing Dose Forms:<br />
coated tab lets 44%<br />
cap sules 13%<br />
vi als 10%<br />
in fu sions 8%<br />
tab lets 7%<br />
NOVARTIS CON SUMER HEALTH-GEBRO<br />
Full Name: Novartis Con sumer Health - Gebro<br />
GmbH<br />
Postal Ad dress: Postfach 25, A-6391<br />
Fieberbrunn<br />
Street Ad dress: Bahnhofbichl, A-6391<br />
Fieberbrunn<br />
Tel: +43 5354 5300 304<br />
Fax: +43 5354 5300 732<br />
Email: pharma@gebro.com<br />
Home Page: www.novartis.at<br />
De scrip tion: Man u fac turer, packager/as sem -<br />
bler, im porter, dis trib u tor, pro moter,<br />
sales/detailer. Prod uct ranges in clude: phar ma -<br />
ceu ti cal prod ucts (branded, pre scrip tion,<br />
non-pre scrip tion), den tal prod ucts, herbal prod -<br />
ucts. Established 1997.<br />
Con tacts (Pharm): Chair man: Gerhard Lotsch;<br />
Com mer cial Op er a tions: Dr Gerhard Loetsch;<br />
Man u fac ture: Dr G. Hantich; Mar ket Re search:<br />
Eva Gamerith; Re search & De vel op ment: Dr E.<br />
Hesse; Gen eral Con tact: Eva Gamerith<br />
Phar ma ceu ti cal Sales: US$ 22-24 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 45-50%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 55-60%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
70-75%<br />
Prin ci pal Prod ucts:<br />
VENORUTON (var i cose ther apy sys temic; var i -<br />
cose ther apy top i cal)<br />
FENISTIL (an ti his ta mine sys temic; antipruritic)<br />
LEMOCIN (throat prep a ra tion)<br />
VIBROCIL (na sal prep a ra tion top i cal)<br />
OTRIVIN (na sal prep a ra tion top i cal)<br />
Ther a peu tic Range:<br />
na sal prep a ra tions 16%<br />
throat prep a ra tions 15%<br />
antivaricosis/antihemorrhoidal prep a ra tions<br />
14%<br />
wound-heal ing agents 7%<br />
antidiarrheals, elec tro lyte re plac ers, in tes ti nal<br />
anti-inflammatorie s 6%<br />
Lead ing Dose Forms:<br />
liq uids 24%<br />
spe cial solid forms 16%<br />
cap sules 14%<br />
tab lets 10%<br />
coated tab lets 9%<br />
SANDOZ<br />
Full Name: Sandoz GmbH<br />
Street Ad dress: Brun ner Strasse 59, A-1235<br />
Wien<br />
Tel: +43 186 659 750<br />
Fax: +43 186 659 792<br />
Home Page: www.sandoz.com<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 151